Arca Biopharma Inc. (NASDAQ: ABIO) stock gains by 2.59% in the current market trading session. ARCA biopharma is committed to using a precision medicine approach to drug production to create genetically tailored treatments for cardiovascular disorders. ARCA is working on rNAPc2 as a possible therapy for severe viral infections, using COVID-19 as the first target.
>> 7 Top Picks for the Post-Pandemic Economy <<
Upcoming Event
Thomas Keuer, Chief Operating Officer of ARCA biopharma, will speak at the Access to Giving Virtual Investor Conference, which will be conducted electronically July 13-15, 2021. With 50+ businesses presenting, a keynote, three separate panels, and one-on-one conversations, Access to Giving is a conference focused on investor education and activism.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Read More
Recent Development
ARCA biopharma has announced that it has signed a patent transfer agreement with Johannes Gutenberg University Mainz’s University Medical Center. ARCA will obtain unique world-wide patent rights to the use of rNAPc2 as a possible therapy for COVID-19 and other signs, based on the studies and findings from the laboratory of Univ.-Prof. Dr. Wolfram Ruf, Scientific Director, and Alexander von Humboldt Professor at the University Medical Center Mainz’s Center for Thrombosis and Hemostasis (CTH).
ARCA is developing rNAPc2, a recombinant protein therapy, as a possible treatment for COVID-19 and other severe viral infections. ASPEN-COVID-19 is a Phase 2b clinical trial that is testing rNAPc2 as a possible therapy for COVID-19 patients. The research of rNAPc2 as a possible COVID-19 therapy has been recognized as a Fast Track development program by the US Food and Drug Administration (FDA).
>> 7 Top Picks for the Post-Pandemic Economy <<
Dr. Michael Bristow, ARCA’s President, and CEO stated,
ABIO is excited to continue working with Dr. Ruf and the researchers at the University Medical Center Mainz to further the development of rNAPc2 as a possible therapy for COVID-19 patients. Despite the existence of vaccinations and the discovery of various variations, individuals worldwide are still suffering from severe COVID-19 infections that necessitate hospitalization. They think that rNAPc2’s anticoagulant, anti-inflammatory, and antiviral characteristics make it a good candidate for treating COVID-19’s effects across several pathways.